Results 131 to 140 of about 45,526 (248)

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 [PDF]

, 1998
Shingo Dan, Mikihiko Naito, Takashi Tsuruo   +2 more
openalex   +1 more source

Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR‐ABL‐positive acute lymphoblastic leukemia in Taiwan [PDF]

, 2002
Bor‐Sheng Ko, Jih‐Lu Tang, Fen‐Yu Lee, Ming‐Chi Liu, Woei Tsai, Yee‐Chun Chen, Chiu‐Hwa Wang, Ming‐Chin Sheng, Dong‐Tsam Lin, Kai‐Hsin Lin, Hwei‐Fang Tien   +10 more
openalex   +1 more source

Additional file 1 of Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

, 2020
Xinhua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, Lujian Liao, Bo Jiao, Ruibao Ren   +9 more
openalex   +1 more source

Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)–induced Apoptosis of Bcr-Abl–positive Human Acute Leukemia Cells [PDF]

, 2019
Ramadevi Nimmanapalli, Mercedes Porosnicu, Diep Nguyen, Elizabeth Worthington, Erica O’Bryan, Charles Perkins, Kapil N. Bhalla   +6 more
openalex   +1 more source

eLife Assessment: RAPSYN-Mediated Neddylation of BCR-ABL Alternatively Determines the Fate of Philadelphia Chromosome-positive Leukemia

, 2023
Amit Kumar Verma
openalex   +1 more source

Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq [PDF]

, 2020
Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease, associated with a reciprocal translocation between chromosomes 9 and chromosome 22, lead to the formation of the BCRABL fusion gene (Philadelphia chromosome).
Musawi, Mohammed Sadeq Mahdi Al-
core  

Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia

Онкогематология
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients.
D. V. Kustova, E. V. Motyko, A. N. Kirienko, T. N. Gert, I. V. Leppyanen, M. P. Bakay, E. V. Efremova, E. V. Morozova, E. G. Lomaia, V. A. Shuvaev, S. V. Sidorkevich, I. S. Martynkevich   +11 more
doaj   +1 more source

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia [PDF]

, 2013
Michaela Scherr, Alex Elder, Karin Battmer, David Barzan, Simon Bomken, Melanie Ricke‐Hoch, Arne Schröder, Letizia Venturini, H J Blair, Josef Vormoor, Oliver G. Ottmann, Arnold Ganser, Andreas Pich, Denise Hilfiker‐Kleiner, Olaf Heidenreich, Matthias Eder   +15 more
openalex   +1 more source

The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity [PDF]

, 1994
The myristoylated form of c-Abl protein, as well as the P210bcr/abl protein, have been shown by indirect immunofluorescence to associate with F-actin stress fibers in fibroblasts. Analysis of deletion mutants of c-Abl stably expressed in fibroblasts maps
Baltimore, David, Jackson, Peter K., Janmey, Paul A., Matsudaira, Paul T., Sanders, Mitchell C., Van Etten, Richard A.   +5 more
core   +4 more sources

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [PDF]

, 2002
Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin Lynch, Timothy P. Hughes   +8 more
openalex   +1 more source